Nitto Denko Avecia Inc. and Nitto Denko Avecia Pharma Services (Nitto Avecia), global leaders in the development and manufacturing of oligonucleotides for the therapeutic market, have announced the appointment of Tammy Cooper as the new President of Nitto Avecia, effective June 21, 2024. Cooper, who currently serves as Vice President of Business Development and Project Management for Nitto Avecia, will report to Yoshihiko Terada, who will be appointed as the Executive Chairman of Nitto Avecia. They will succeed the current President, Seiji Fujioka, who will remain as President during the transitional period. After June 21, 2024, Mr. Fujioka will continue as the Executive Vice President of Nitto Denko Corporation and oversee the South Asia region, including India and Oceania.
Terada has been working for Nitto Denko for nine years, holding positions such as the Head of Personnel for Nitto Avecia and Vice President of Nitto Denko. Prior to joining Nitto Denko, Terada gained extensive experience in the pharmaceutical industry and management consultancy.
Cooper brings a wealth of experience in the pharmaceutical field, starting her career as a formulation chemist for small molecule manufacturing. Over her 19-year tenure at Nitto Avecia, she has held positions of increasing responsibility in marketing, business development, and project management. Most recently, she served as Vice President of Business Development and played a vital role in Nitto Avecia’s recent period of rapid growth.
Expressing her honor at becoming the first female President of Nitto Avecia, Cooper stated, “I am inspired by the limitless possibilities for our company and the dedication, resilience, and commitment of our employees. Through our culture of innovation, we will continue to drive oligonucleotide development and manufacturing to new heights of success.”
Terada added, “The prospects for the oligonucleotide market are extremely positive, offering Nitto Avecia and Nitto Avecia Pharma Services great partnership opportunities with our clients on life-changing and life-saving pharmaceutical products. I look forward to continuing to work with this exceptional team to contribute to patient well-being and the oligonucleotide market.”
Both Terada and Cooper will be based at Nitto Avecia’s headquarters in Milford, Massachusetts.
Source: Nitto Avecia Inc.
Nitto Denko Avecia Inc. and Nitto Denko Avecia Pharma Services have appointed Tammy Cooper as the new President of Nitto Avecia, effective June 21, 2024. Cooper, who currently serves as Vice President of Business Development and Project Management for Nitto Avecia, will bring her extensive experience in the pharmaceutical field to the role. She began her career as a formulation chemist and has held various positions in marketing, business development, and project management during her 19-year tenure at Nitto Avecia. Cooper’s appointment makes her the first female President of Nitto Avecia, showcasing the company’s commitment to diversity and gender equality.
Yoshihiko Terada, the current Vice President of Nitto Denko and former Head of Personnel for Nitto Avecia, will assume the position of Executive Chairman of Nitto Avecia. Terada has been with Nitto Denko for nine years and has experience in the pharmaceutical industry and management consultancy. The addition of Terada and Cooper to the leadership team signals a strong focus on driving growth and innovation in the oligonucleotide market.
The oligonucleotide market holds promising prospects, offering Nitto Avecia and Nitto Avecia Pharma Services excellent partnership opportunities with clients for the development of life-changing and life-saving pharmaceutical products. The appointment of new leadership aligns with the company’s goal of contributing to patient well-being and further advancing oligonucleotide development and manufacturing.
Some key challenges and controversies associated with the subject include the intense competition in the oligonucleotide market, the need for regulatory approvals, and the potential risks associated with the development and manufacturing processes. The market also faces ongoing discussions surrounding intellectual property rights, as companies seek to protect their innovations and maintain a competitive edge. It is essential for Nitto Avecia to navigate these challenges while staying at the forefront of technological advancements and maintaining strong client partnerships.
For more information on Nitto Avecia and its role in the oligonucleotide market, you can visit their official website: Nitto Avecia.